MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ph19081216

Медицинская библиотека · Pharmaceuticals (Basel, Switzerland) · 2026

Design, Synthesis, In Vitro and In Vivo Evaluation of Novel Anti-Alzheimer's (1E,4E)-1,5-Bis[(het)aryl]penta-1,4-dien-3-one Derivatives.

Mendes Géssica Oliveira, Bento Lucas Diego Pereira, Oliveira Thiago Malverde de, Barbosa Deyse Brito, Tsui Guilherme Saraiva, Gomes Ellen Nunes, Sales Raphaela Oliveira, Rocha Mateus Silva de Castro, Silva Michel Pires da, Oliveira Tiago Alves de, Maia Eduardo Habib Bechelane, Falkoski Daniel Luciano, Marra Isabella Flores de Souza, Andrade Lorena Silva Matos, Mendes Liliane Costa Vanessa Pereira, Fonseca Bianca de Souza, Oliveira Lucas Matheus Gonçalves de, Silva Victor Diogenes Amaral da, Carvalho Paulo Batista de, Silva Alisson Marques da, Taranto Alex Gutterres, Damázio Laila Cristina Moreira, Valle Marcelo Siqueira, Leite Franco Henrique Andrade

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

Alzheimer's disease (AD) is a progressive, multifactorial neurodegenerative condition characterized by neurofibrillary tangles, neuronal loss, cognitive impairment, and accumulation of β-amyloid plaques. Considering the limitations of current treatments, which present adverse effects and only alleviate symptoms without modifying disease progression, there is an urgent need for new therapeutic approaches. This study aimed to investigate the neuroprotective potential of synthetic derivatives of (1E,4E)-1,5-bis[(het)aryl]penta-1,4-dien-3-ones, focusing on the inhibition of the cholinesterase enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), targets directly related to the cholinergic deficit observed in AD.

Methods

The compounds were initially synthesized by aldol condensation reactions, with subsequent physicochemical characterization. They were then subjected to in silico assays that demonstrated high binding affinity to the active sites of AChE and BChE. The derivatives were evaluated in vitro for their inhibitory activity on these enzymes and in vivo in an experimental model of AD induced by streptozotocin in Wistar rats.

Results

The synthesized derivatives showed favorable predicted interactions with the active sites of AChE and BChE, supporting their potential as cholinesterase inhibitors. In vitro assays demonstrated inhibitory activity against both enzymes, with selected derivatives showing improved activity compared with the parent scaffold. In the in vivo model, treatment with the selected compounds was associated with neuroprotective effects, suggesting preservation of nervous tissue integrity under AD-like conditions.

Conclusions

These findings indicate that derivatives may represent promising candidates for further investigation as multitarget agents for AD. The study reinforces the relevance of integrating organic synthesis, molecular modeling, enzymatic assays, and in vivo evaluation in the search for new therapeutic strategies for neurodegenerative diseases.

Для цитирования: Mendes Géssica Oliveira, Bento Lucas Diego Pereira, Oliveira Thiago Malverde de, Barbosa Deyse Brito, Tsui Guilherme Saraiva, Gomes Ellen Nunes, Sales Raphaela Oliveira, Rocha Mateus Silva de Castro, Silva Michel Pires da, Oliveira Tiago Alves de, Maia Eduardo Habib Bechelane, Falkoski Daniel Luciano, Marra Isabella Flores de Souza, Andrade Lorena Silva Matos, Mendes Liliane Costa Vanessa Pereira, Fonseca Bianca de Souza, Oliveira Lucas Matheus Gonçalves de, Silva Victor Diogenes Amaral da, Carvalho Paulo Batista de, Silva Alisson Marques da, Taranto Alex Gutterres, Damázio Laila Cristina Moreira, Valle Marcelo Siqueira, Leite Franco Henrique Andrade. Design, Synthesis, In Vitro and In Vivo Evaluation of Novel Anti-Alzheimer's (1E,4E)-1,5-Bis[(het)aryl]penta-1,4-dien-3-one Derivatives.. Pharmaceuticals (Basel, Switzerland). 2026. DOI: 10.3390/ph19081216.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.